Pharmaceuticals

Global Biologic & Biosimilar RA Drugs Market Trends and Forecast 2026–2030

March 18, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Biologic & Biosimilar RA Drugs Market Projected To Become By 2030 Based On Its 2026 Valuation?

The market size for biologic & biosimilar ra drugs has demonstrated robust growth over recent years. This market is projected to expand from $14.57 billion in 2025 to $15.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Historically, this expansion has been driven by factors such as the increasing prevalence of rheumatoid arthritis, the constrained availability of treatment alternatives, heightened investment in biologics research, rising healthcare spending, and the expiration of patents for significant biologics.

The biologic & biosimilar ra drugs market is projected for significant expansion in the coming years, with its size expected to reach $20.53 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.2%. This growth during the forecast period is attributed to factors such as the increasing adoption of biosimilars, technological advancements in drug delivery, expansion of manufacturing capacities, regulatory support for biologics, and increasing awareness of precision medicine. Major trends anticipated for the forecast period include personalized biologic therapies, acceleration in biosimilar adoption, advanced drug delivery systems, regulatory harmonization for biologics, and cost optimization in ra treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9255&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Biologic & Biosimilar RA Drugs Market?

The escalating healthcare spending is projected to stimulate the growth of the biologic & biosimilar RA drug market moving forward. This expenditure represents the cumulative financial outlay by individuals, governments, and organizations on medical goods and services, including costs for the prevention, treatment, and management of various health conditions. Biologic and biosimilar RA drugs play a crucial role in optimizing rheumatoid arthritis management by balancing efficacy and cost-effectiveness for the specialized and often expensive treatments covered by healthcare spending. For example, in November 2023, the CIHI, a Canada-based Institute for Health Information, indicated that Canada’s total health spending is anticipated to reach $344 billion in 2023, equivalent to $8,740 per Canadian. This marks a 2.8% increase in 2023, building on a modest 1.5% growth registered in 2022. Thus, the continuous rise in healthcare spending is propelling the biologic & biosimilar RA drug market.

What Segment Groups Are Identified Within The Biologic & Biosimilar RA Drugs Market?

The biologic & biosimilar ra drugs market covered in this report is segmented –

1) By Source: Microbial, Mammalian, Other Sources

2) By Manufacturing: Outsourced, In-House

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Microbial: Bacterial Sources, Fungal Sources, Yeast Sources

2) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cell Lines

3) By Other Sources: Plant-Based Sources, Insect-Based Sources, Synthetic Biology Approaches

What Trends Are Advancing Progress In The Biologic & Biosimilar RA Drugs Market?

Leading companies within the biologic & biosimilar RA drugs market are concentrating on creating advanced solutions, such as dual-concentration biosimilar formulations. This effort aims to address the growing need for more economical, accessible, and user-friendly substitutes for expensive biologics. Dual-concentration biosimilar choices provide both elevated and reduced strength formulations, mirroring those of branded biologics, which facilitates uninterrupted treatment progression and superior patient comfort compared to conventional single-concentration biologics. For instance, in July 2023, Organon, a US-based healthcare firm, and Samsung Bioepis, a South Korea-based biopharmaceutical enterprise, introduced HADLIMA, a biosimilar version of Humira (adalimumab), in the United States. HADLIMA, offered in both high and low concentrations, is designed to improve availability and affordability for individuals suffering from autoimmune conditions. This biosimilar is retailed at an 85% lower price than Humira, thereby broadening patient reach. HADLIMA incorporates an autoinjector, acknowledged by the Arthritis Foundation, and a patient assistance initiative, HADLIMA For You, which provides educational materials and co-payment aid. It is prescribed for various ailments, including rheumatoid arthritis and Crohn’s disease. HADLIMA is offered in both citrate-free high concentration (100 mg/mL) and citrate-containing low concentration (50 mg/mL), ensuring continuous care for patients.

Which Companies Hold Significant Positions In The Biologic & Biosimilar RA Drugs Market?

Major companies operating in the biologic & biosimilar ra drugs market are Samsung BioLogics Co. Ltd., Amgen Inc., AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., Eli Lilly and Company, Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Stada Arzneimittel AG, Boehringer Ingelheim Pharmaceuticals Inc., Gedeon Richter Plc., La Roche Ltd., Regeneron Pharmaceuticals Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Biogen Inc., Genentech Inc., GlaxoSmithKline plc, Mylan N.V., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Biocon Ltd., Coherus BioSciences Inc.

Read the full biologic & biosimilar ra drugs market report here:

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Which Regions Are Projected To Dominate The Biologic & Biosimilar RA Drugs Market In The Coming Years?

North America was the largest region in the biologic & biosimilar RA drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the biologic & biosimilar RA drugs market report during the forecast period. The regions covered in the biologic & biosimilar ra drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biologic & Biosimilar RA Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9255&type=smp

Browse Through More Reports Similar to the Global Biologic & Biosimilar RA Drugs Market 2026, By The Business Research Company

Biologic And Biosimilar Ra Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologic-and-biosimilar-ra-drugs-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Rheumatoid Arthritis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795